Clearmind Medicine Inc. (NASDAQ:CMND) jumped 54.8% in premarket trading after announcing that Hadassah Medical Center in Jerusalem has granted final approval to participate in the company’s Phase 1/2a clinical study of CMND-100.
The investigational therapy, CMND-100, is an oral drug candidate based on the company’s MEAI molecule and is being developed as a potential treatment for Alcohol Use Disorder (AUD). With this approval, Hadassah Medical Center officially joins the ongoing multinational trial, which has already completed dosing in its first patient cohort.
The study is being conducted in collaboration with several leading medical institutions, including Yale School of Medicine’s Department of Psychiatry, Johns Hopkins University School of Medicine, and Tel Aviv Sourasky Medical Center. At Hadassah-University Medical Center, the research will be overseen by Prof. Joseph Caraco, Director of the Clinical Pharmacology Unit.
Clearmind’s Phase 1/2a trial is designed to evaluate the safety, tolerability, and pharmacokinetics of CMND-100, while also exploring whether the therapy can help reduce alcohol cravings and consumption among patients diagnosed with AUD.
The company highlighted the urgency of advancing new treatment options, noting that Alcohol Use Disorder is responsible for 4.7% of all deaths globally, according to the World Health Organization. Clearmind said it expects continued momentum in enrollment and data collection as additional clinical sites initiate participation.